China’s New $1,500 Exoskeleton Could Make Wheelchairs Obsolete
A woman with muscular dystrophy tried on a robotic hip exoskeleton at the Canton Fair in China, stood up, and walked across the convention floor — wearing a device that costs under fifteen hundred dollars. The video explains how that price compares to the roughly eighty-five to one hundred and nine thousand dollars charged for comparable Western medical exoskeletons, and why the gap exists. The core argument is that two Shenzhen companies, DNSYS and Hypershell, achieved low prices not through cheap labor but by borrowing motors, harmonic gearboxes, and motion sensors already mass-produced for drones, e-bikes, and humanoid robots. DNSYS went from a sixty-thousand-dollar hospital machine to a consumer model under seven hundred dollars in about three years. The video is clear that consumer models are not FDA-cleared and are not substitutes for clinically approved devices for people with spinal cord injuries or neurological conditions, though it suggests a middle tier aimed at older adults could emerge within three to five years.
China’s New $1,500 Exoskeleton Could Make Wheelchairs Obsolete
A woman with muscular dystrophy tried on a robotic hip exoskeleton at the Canton Fair in China, stood up, and walked across the convention floor — wearing a device that costs under fifteen hundred dollars. The video explains how that price compares to the roughly eighty-five to one hundred and nine thousand dollars charged for comparable Western medical exoskeletons, and why the gap exists. The core argument is that two Shenzhen companies, DNSYS and Hypershell, achieved low prices not through cheap labor but by borrowing motors, harmonic gearboxes, and motion sensors already mass-produced for drones, e-bikes, and humanoid robots. DNSYS went from a sixty-thousand-dollar hospital machine to a consumer model under seven hundred dollars in about three years. The video is clear that consumer models are not FDA-cleared and are not substitutes for clinically approved devices for people with spinal cord injuries or neurological conditions, though it suggests a middle tier aimed at older adults could emerge within three to five years.